Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Jay D. Hatfield, CEO of Infrastructure Capital Advisors, says he's "bullish on financials, but more bullish on investment banks," as he expects not only an M&A boom "because of more reasonable ...

Jay D. Hatfield, CEO of Infrastructure Capital Advisors, said strong net interest margins for banks and "AI upside" for tech are why he's bullish on those companies' stocks. Could AI-assisted program ...

Macy's CEO Tony Spring, who is trying to turn around the company, wants to prove to the public markets that its three-brand ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...

CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...